Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...
Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating ...
Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...
Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...
Advanced artificial intelligence genetics models have been successfully applied to Parkinson’s disease at CCGC.
Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...
The FDA approved a monthly maintenance dosing of intravenous lecanemab (Leqembi) for early Alzheimer's disease, said ...
New research reveals a significant reduction in Parkinson’s disease risk among autoimmune patients treated with anti-TNF or ...
Anavex’s newest patent will be expected to remain in force at least until July 2039, not including any patent term extensions. It will expand and supplement the current ANAVEX®2-73 (blarcamesine) ...
Hosted on MSN4d
Parkinson's disease could be treated by FDA-approved cancer drug after major research breakthroughA major research breakthrough on Parkinson's disease revealed that an already FDA-approved cancer drug could help stem the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback